EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From reactive to predictive: Advancing biologic dosing in dermatology

Anke Eylenbosch iD, Ruoheng Wei, Rani Soenen, Catherine Smith iD, Joseph F Standing, Satveer Mahil, Jo Lambert iD

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70147 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Anke Eylenbosch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Skin, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Drug Monitoring, Skin Diseases, Dermatology, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: NIHR Senior Investigator Award, British Skin Foundation, NIHR Advanced Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologic therapies are targeted immunomodulators that have revolutionised the treatment of chronic inflammatory dermatoses, including psoriasis, hidradenitis suppurativa and atopic dermatitis, offering high efficacy and safety for moderate‐to‐severe disease. However, standardised dosing regimens fail to account for inter‐individual heterogeneity, leading to non‐optimal drug exposure in certain patients. This may, in part, explain why primary non‐response, secondary loss of response or adverse effects are observed in real‐world practice. While empirical off‐label adjustments are commonly employed, data‐driven dosing optimisation may enable better disease control and reduce the burden of lifelong biologic treatment by avoiding excessive dosing. Therapeutic drug monitoring (TDM) involves adjusting doses based on serum drug concentrations to maintain therapeutic ranges, relying on established dose–exposure–response correlations. Although TDM provides reactive or proactive optimisation approaches, its threshold‐based adjustments are limited by an inability to predict individual pharmacokinetic variability or future clinical outcomes. Model‐informed precision dosing (MIPD) represents an evolution beyond conventional TDM by integrating population pharmacokinetic–pharmacodynamic models, patient‐specific characteristics and Bayesian forecasting to deliver personalised, adaptive dosing recommendations. This approach captures inter‐individual variability while linking serum drug concentrations to clinical response, enabling proactive dose adjustments using sparse or non‐steady‐state data. Emerging digital tools, point‐of‐care testing and integration of pharmacogenomics and biomarker profiling are expected to enhance MIPD’s precision and accessibility. Once implemented in routine care, MIPD has the potential to transform biologic therapy dosing using a dynamic, patient‐centric system that maximises clinical response, minimises overtreatment and supports sustainable healthcare delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringSkin DiseasesDermatologyBiological ProductsDermatologic AgentsHumansDose-Response Relationship, DrugPsoriasis

Stichwörter der Autor:innen

adalimumabbiological productsmodel‐informed precision dosingpsoriasistherapeutic drug monitoringustekinumab

Substanzen

Biological ProductsDermatologic Agents

Autor:innen und Institutionen

  • Department of Head and Skin, Ghent University Hospital, Ghent, Belgium.
  • St John's Institute of Dermatology, King's College London, London, UK.
  • Department of Infection, Immunity and Inflammation, University College London, London, UK.

ORCID-Profile: Anke Eylenbosch, Catherine Smith, Jo Lambert

Förderung

  • NIHR Senior Investigator Award
  • British Skin Foundation
  • NIHR Advanced Fellowship
  • Fonds Wetenschappelijk Onderzoek
  • COST action ENOTTA CA21147

Zitieren

APA

Eylenbosch, A., Wei, R., Soenen, R., Smith, C., Standing, J. F., Mahil, S., & Lambert, J. (2026). From reactive to predictive: Advancing biologic dosing in dermatology. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70147

Vancouver

Eylenbosch A, Wei R, Soenen R, Smith C, Standing JF, Mahil S, et al. From reactive to predictive: Advancing biologic dosing in dermatology. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70147

BibTeX
@article{Eylenbosch2026,
  author = {Eylenbosch, Anke and Wei, Ruoheng and Soenen, Rani and Smith, Catherine and Standing, Joseph F and Mahil, Satveer and Lambert, Jo},
  title = {From reactive to predictive: Advancing biologic dosing in dermatology},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70147}
}
Kostenlos starten →